ClinicalTrials.gg
CompletedNCT01620203Updated Nov 18, 2023

Observational Study in Preterm Infants With Intracranial Hemorrhage

An observational study in Intracranial Hemorrhage, Intraventricular Hemorrhage and Cerebral Hypoxia, sponsored by Nelson Claure. Completed at 1 site in United States. Open to participants aged 1 Day to 28 Days. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Nelson Claure · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
27
Ages
1 Day to 28 Days
Sex
All
01

Study summary

Intracranial Hemorrhage (ICH) is an important morbidity affecting premature infants and can have considerable effects on neurodevelopmental outcome.

The investigators showed that preterm infants with severe ICH have decreased cerebral oxygenation several weeks after the hemorrhage. The mechanisms involved in this state of decreased cerebral oxygenation in preterm infants and the effects on cerebral function are unknown.

This longitudinal observation study will evaluate physiologic parameters to determine trends in cerebral oxygenation and function in preterm infants with ICH in comparison to infants without ICH.

02

Conditions studied

  • Intracranial Hemorrhage
  • Intraventricular Hemorrhage
  • Cerebral Hypoxia

Keywords

  • Premature infants
  • Intracranial hemorrhage
  • Intraventricular hemorrhage
  • Cerebral oxygenation
  • Brain function
  • Cerebral perfusion
03

In context

Intracranial Hemorrhages

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

This study's enrollment of 27 is below the median of 250 across 85 observational studies indexed under Intracranial Hemorrhages.

Browse Intracranial Hemorrhages studies →

Lead sponsor

This is the only study on the registry with Nelson Claure as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Preterm infants admitted to the newborn intensive care unit at Holtz Children's Hospital of the Jackson Memorial Hospital/University of Miami Medical Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born between 23 and 28 weeks of gestation
  • Diagnosed with ICH grades II or higher during the first week after birth
  • Matched control infants without ICH.

Exclusion criteria

Exclusion Criteria:

  • Major congenital malformations
  • Birth asphyxia
  • Not expected to survive
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
27 participants (actual)

Groups and cohorts

  • Control

    Matched group of control infants without diagnosis of intracranial hemorrhage

    Other: No intervention/treatment is given

  • Intracranial Hemorrhage

    Group of preterm infant with diagnosis of intracranial hemorrhage.

    Other: No intervention/treatment is given

Interventions

  • OtherNo intervention/treatment is given
06

What researchers measure

Primary outcomes

  1. Change in cerebral oxygenation

    Comparison of the progression of cerebral oxygenation measured non-invasively by near infrared spectroscopy over time in infants with ICH and non-ICH infants.

    Time frame: postnatal weeks 4 and 8

Secondary outcomes

  1. Change in cerebral perfusion and function

    Comparisons of ultrasound measurements of superior vena cava flow and brain electrical activity by electroencephalography over time in infants with ICH and non-ICH infants.

    Time frame: post natal weeks 4 and 8

07

Study locations

1 site
  • Holtz Children's Hospital, Jackson Memorial Hospital/University of Miami Medical Center
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Nov 2023, 137 months.

Of 44 non-industry observational studies under Intracranial Hemorrhages, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 130. This study's 137 months is above that.

Counting every sponsor, half of 49 studies reached it within 59 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 15, 2012
StartActual
Jun 2012
Primary completionActual
Nov 1, 2023
CompletionActual
Nov 1, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01620203
Lead sponsor
Nelson Claure
Responsible party
Nelson Claure (Research Associate Professor of Pediatrics, University of Miami) — Sponsor-investigator
First posted
Jun 15, 2012
Start date
Jun 2012
Primary completion
Nov 1, 2023
Completion
Nov 1, 2023
Last update
Nov 18, 2023

Study contacts

Nelson Claure, M.Sc.,Ph.D.
principal investigator · University of Miami
Eduardo Bancalari, M.D.
principal investigator · University of Miami
Deepak Jain, M.D.
principal investigator · University of Miami
Sethuraman Swaminathan, M.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion